SEARCH

SEARCH BY CITATION

References

  • 1
    Juul-Möller S. SYNCOPE – A complex syndrome of several causes. J Intern Med 2013; 273: 3201.
  • 2
    Chapple CR, Wyndaele JJ, Nordling J, Boeminghaus F, Ypma AF, Abrams P. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 1996; 29: 15567.
  • 3
    McConnell JD, Roehrborn C, Bautista OM et al. The long-term effect of Doxazosin, Finasteride, and combination therapy on the clinical progression of benign prostatic Hyperplasia. N Eng J Med 2003; 349: 238798.
  • 4
    Yuan J, Liu Y, Yang Z, Qin X, Yang K, Mao C. The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews. Curr Med Res Opin 2013; 29: 27987.
  • 5
    Fwu CW, Eggers PW, Kaplan SA, Kirkali Z, Lee JY, Kusek JW. Long-term effects of doxazosin, finasteride, and combination therapy on quality of life in men with benign prostatic hyperplasia. J Urol 2013 (in press, accepted manuscript) doi: 10.1016/j.juro.2013.01.061.
  • 6
    Verhamme KM, Dieleman JP, Bleumink GS et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care–the Triumph project. Eur Urol 2002; 42: 3238.